NCT03642574 is a NA clinical trial of CNV in DNA Methylation, sponsored by Chen Zi-Jiang.

Who is sponsoring NCT03642574?

NCT03642574 is sponsored by Chen Zi-Jiang.

What drugs are being tested in NCT03642574?

Interventions in NCT03642574: CNV.

What condition does NCT03642574 study?

NCT03642574 studies DNA Methylation.

Is NCT03642574 still recruiting?

NCT03642574 is currently completed. Last updated 4 October 2022.

Last reviewed 2022-10-04 · How we verify

NCT03642574

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preimplantation DNA Methylation Test (PIMT) in ART

Completed NA Last updated 4 October 2022

What this trial tests

NA trial testing CNV in DNA Methylation in 182 participants. Completed in 30 June 2022.

Timeline

5 September 2018

Primary endpoint
28 August 2021

30 June 2022

Quick facts

Lead sponsor	Chen Zi-Jiang
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	182
Start date	5 September 2018
Primary completion	28 August 2021
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

Conditions studied

DNA Methylation — all drugs for DNA Methylation →

Sponsor

Chen Zi-Jiang

Who can join

20 and older, female only, with DNA Methylation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to determine the safety and effect of methylation level of DNA methylation in embryos on the outcome of assisted reproductive technology (ART) during blastocyst embryo screening. Subjects with blastocysts on day 5-7 of embryo culture will be biopsied. A Freeze-all strategy and a single frozen blastocyst transfer will be performed till all study-specific embryos have been transferred. Then whole genome bisulfate sequencing will be performed on all cells that obtained from biopsy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A clinical study of preimplantation DNA methylation screening in assisted reproductive technology.
Gao Y, Yi L, Zhan J, Wang L, et al · · 2023 · cited 14× · PMID 37150776 · DOI 10.1038/s41422-023-00809-z

Verify or expand the search:

Other recruiting trials for DNA Methylation

Currently open trials in the same condition.

NCT07224854 — Epigenetic Signature for CRC Early Detection · active not recruiting
NCT06140992 — PaCIFiC-CUP Classifies Cancer of Unknown Primary · recruiting
NCT05737953 — Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples · recruiting
NCT06476067 — Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma · recruiting
NCT06490003 — Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03642574 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chen Zi-Jiang
Last refreshed: 4 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03642574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing